Sirona Biochem Initiates Significant Corporate Changes
June 15 2022 - 8:00AM
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF)
(“
Sirona”) is pleased to inform about several
significant corporate changes currently in preparation:
Now that Sirona Biochem has closed an exclusive
global licencing agreement with Allergan Aesthetics, the next steps
for sustainable and rapid growth of the company are initiated.
The Board has begun a strategic review of every
facet of the company including management, organizational
structure, project pipeline, financial position and the exchanges
on which the Sirona shares are listed.
Organizational changes and management expansion
will occur in both, our headquarters in Vancouver, Canada and our
research facility in Rouen, France. External resources will be
engaged to assist and there will be updates communicated throughout
the remainder of 2022.
Sirona Biochem will ramp-up and accelerate the
pipeline development in France. Our science team and CSO, Dr.
Geraldine Deliencourt-Godefroy, have a backlog of projects underway
and further potential projects that our technology can be applied
to. Expertise will be brought in to conduct a review of the lab
with the goal to maximize our talent and improve speed to market.
We are already in advanced discussions with an experienced expert
from the pharmaceutical industry.
We will increase our presence on several fronts.
We will seek institutional analysis and investment in Canada, USA
and EU and improve our visibility to our current investors. We will
also expand our presence in the biotech community to bring in new
partnerships through attendance at industry events, improved
marketing materials and an overhaul of our professional company
image.
Up listing remains a goal of Sirona and we are
actively taking steps to achieve the necessary requirements. The
changes we are implementing, and the value increase we will
achieve, will help meet these requirements.
Sirona Biochem will provide continuous
information on the measures implemented.
About Sirona Biochem
Corp.Sirona Biochem is a cosmetic ingredient and drug
discovery company with a proprietary platform technology. Sirona
specializes in stabilizing carbohydrate molecules with the goal of
improving efficacy and safety. New compounds are patented for
maximum revenue potential.
Sirona’s compounds are licensed to leading
companies around the world in return for licensing fees, milestone
fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is
in France and is the recipient of multiple French national
scientific awards and European Union and French government grants.
For more information, please visit www.sironabiochem.com.
For more information regarding this press
release, please contact:
Investor Enquiries:Jonathan WilliamsManaging
DirectorMomentum PRPhone: 1.450.332.6939Email:
jwilliams@momentumpr.com
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Sirona Biochem cautions you that statements
included in this press release that are not a description of
historical facts may be forward-looking statements. Forward-looking
statements are only predictions based upon current expectations and
involve known and unknown risks and uncertainties. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of release of the
relevant information, unless explicitly stated otherwise.
Actual results, performance or achievement could differ materially
from those expressed in, or implied by, Sirona Biochem’s
forward-looking statements due to the risks and uncertainties
inherent in Sirona Biochem’s business including, without
limitation, statements about: the progress and timing of its
clinical trials; difficulties or delays in development, testing,
obtaining regulatory approval, producing and marketing its
products; unexpected adverse side effects or inadequate therapeutic
efficacy of its products that could delay or prevent product
development or commercialization; the scope and validity of patent
protection for its products; competition from other pharmaceutical
or biotechnology companies; and its ability to obtain additional
financing to support its operations. Sirona Biochem does not assume
any obligation to update any forward-looking statements except as
required by law.
Sirona Biochem (TSXV:SBM)
Historical Stock Chart
From Jul 2024 to Aug 2024
Sirona Biochem (TSXV:SBM)
Historical Stock Chart
From Aug 2023 to Aug 2024